Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Completes Assays for Tacere, Pfizer RNAi Drug Alliance

Premium

Exiqon announced this week that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.

As reported by RNAi News early last year, Tacere licensed its preclinical hepatitis C therapy TT-033 to Pfizer worldwide except in Asia, where Oncolys BioPharma has the drug's rights (see RNAi News, 1/10/2008).

According to Exiqon, the assays will be used to "assess critical performance points for the RNAi therapeutic in a preclinical setting."

Specific terms of the arrangement with Tacere were not disclosed.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.